1
|
Grossman D, Raifman S, Morris N, Biggs MA, Arena A, Bachrach L, Beaman J, Collins A, Gold M, Hannum C, Ho S, Middleton T, Schwarz EB, Tocce K, Seibold-Simpson S, Sobota M, Wohler D. P025Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment. Contraception 2022. [DOI: 10.1016/j.contraception.2022.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Johnstone KM, Middleton T, Kemps E, Chen J. A pilot investigation of universal school‐based prevention programs for anxiety and depression symptomology in children: A randomized controlled trial. J Clin Psychol 2020; 76:1193-1216. [DOI: 10.1002/jclp.22926] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Tracey Middleton
- School of Psychology Flinders University Adelaide South Australia Australia
| | - Eva Kemps
- School of Psychology Flinders University Adelaide South Australia Australia
| | - Junwen Chen
- Research School of Psychology Australian National University Canberra Australian Capital Territory Australia
| |
Collapse
|
3
|
Middleton T, Turner L, Fennell C, Savkovic S, Jayadev V, Conway AJ, Handelsman DJ. Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol 2015; 172:511-7. [PMID: 25637074 DOI: 10.1530/eje-14-0891] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Injectable testosterone undecanoate (TU) was marketed within the last decade, but its complications in routine clinical practice are not well defined. DESIGN AND METHODS Prospective observational study of consecutive TU injections in an Andrology Clinic to estimate the incidence of i) immediate cough/syncope due to pulmonary oil microembolisation (POME), ii) post-injection haematoma and iii) the prevalence of secondary polycythaemia. RESULTS In 3022 injections given to 347 patients over 3.5 years, POME was observed after 56 injections (66% mild, 19% severe; 40% with onset before injection completed) in 43 patients. The incidence of 19 (95% CI 14-24) per 1000 injections did not differ between three experienced nurse injectors, but recurrences were more frequent than by chance. No post-injection haematoma was reported including after 269 injections to men taking antiplatelet, anticoagulant or both drugs (upper 95% confidence limit 1%) with 56 not withholding drugs prior to TU administration (upper 95% confidence limit 5.4%). Mean haematocrit was 0.44±0.04 (s.d.) with 25 (7%) >0.50, 14 (4%) >0.52 and 3 (1%) >0.54. CONCLUSION TU injections produce a low incidence of POME with injections by experienced nurses, but recurrence is more frequent than by chance. Post-injection haematoma was not observed even among men using anticoagulant and/or antiplatelet drugs, and polycythaemia was a minor problem rarely requiring treatment other than optimising inter-injection interval.
Collapse
Affiliation(s)
- T Middleton
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| | - L Turner
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| | - C Fennell
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| | - S Savkovic
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| | - V Jayadev
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| | - A J Conway
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| | - D J Handelsman
- Andrology DepartmentANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales 2139, Australia
| |
Collapse
|
4
|
Westhorpe CLV, Schneider HG, Dunne M, Middleton T, Sundararajan V, Spelman T, Carter V, Crowe SM, Dart A, Mijch A, Kotsanas D, Woolley I. C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sex Health 2014; 11:580-2. [PMID: 25435195 DOI: 10.1071/sh14130] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2014] [Accepted: 10/03/2014] [Indexed: 01/08/2023]
Abstract
UNLABELLED Background In some studies HIV infection confers approximately two-fold higher risk of cardiac events compared with the general population. C-reactive protein (CRP) is a well-characterised biomarker of cardiac events in the general population and is also elevated in patients with HIV infection. The aim of this study was to determine the predictive value of CRP for cardiac events in HIV-infected individuals. METHODS We retrospectively analysed CRP levels in stored plasma samples from HIV-infected patients who did or did not experience a coronary event in a case-controlled manner. All CRP measurements were performed using a high-sensitivity assay (hs-CRP). RESULTS Of the study participants with samples available, we found slightly elevated hs-CRP levels in the cardiac cases (median 3.5, IQR 1.6-14.4, n=23) compared with controls (median 2.6, IQR1.2-8.3, n=49) which were shown to not be statistically significant P=0.20. Analysis of CRP as a binary variable (≥5mgL(-1)) was also not statistically significant (OR: 1.32, 95% CI 0.48-3.63). CONCLUSIONS CRP levels may indicate elevated risk of future cardiac events, however this must be interpreted with caution due to the generalised elevation of CRP during HIV infection. CRP has no predictive value for atherosclerosis, and further research is required to improve early prediction of cardiovascular disease in HIV infection.
Collapse
Affiliation(s)
- Clare L V Westhorpe
- Macfarlane Burnet Institute for Medical Research and Public Health, Prahran, Vic. 3004, Australia
| | - Hans G Schneider
- Alfred Pathology Service, Alfred Health, Commercial Road, Prahran, Vic. 3004, Australia
| | - Mandy Dunne
- Macfarlane Burnet Institute for Medical Research and Public Health, Prahran, Vic. 3004, Australia
| | - Tracey Middleton
- Victorian Infectious Diseases Reference Laboratory, Wreckyn Street, North Melbourne, Vic. 3051, Australia
| | - Vijaya Sundararajan
- Department of Human Services Victoria, Lonsdale Street, Melbourne, Vic. 3000, Australia
| | - Tim Spelman
- Macfarlane Burnet Institute for Medical Research and Public Health, Prahran, Vic. 3004, Australia
| | - Vanessa Carter
- Department of Nutrition, The Alfred Hospital, Commercial Road, Prahran, Vic. 3004, Australia
| | - Suzanne M Crowe
- Macfarlane Burnet Institute for Medical Research and Public Health, Prahran, Vic. 3004, Australia
| | - Anthony Dart
- Department of Cardiology, The Alfred Hospital, Commercial Road, Prahran, Vic. 3004, Australia
| | - Anne Mijch
- Department of Medicine, Central and Eastern Clinical School, Monash University, Melbourne, Vic. 3004, Australia
| | - Despina Kotsanas
- Department of Infectious Diseases, Monash Health, Clayton Road, Clayton, Vic. 3168, Australia
| | - Ian Woolley
- Department of Medicine, Central and Eastern Clinical School, Monash University, Melbourne, Vic. 3004, Australia
| |
Collapse
|
5
|
Middleton T, Lim H, Montgomery D, Rockway T, Liu D, Klein L, Qin W, Harlan J, Kati W, Molla A. Azapteridine Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. LETT DRUG DES DISCOV 2007. [DOI: 10.2174/157018007778992937] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
6
|
Middleton T, Rubin S, Cremer M. Knowledge and use of contraceptives and sterilization in a community El Salvador. Contraception 2005. [DOI: 10.1016/j.contraception.2005.06.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Ryan CE, Elliott JH, Middleton T, Mijch AM, Street AC, Hellard M, Crofts N, Crowe SM, Oelrichs RB. The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia. AIDS Res Hum Retroviruses 2004; 20:1364-7. [PMID: 15650430 DOI: 10.1089/aid.2004.20.1364] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The proportion of human immunodeficiency virus type 1 (HIV-1) among Vietnamese injecting drug users (IDUs) in Melbourne, Australia exceeds that of the background population. To investigate the molecular epidemiology of HIV-1 among this group, the C2-V4 region of the HIV-1 envelope was directly sequenced from 11 Vietnamese Australians and 19 non-Vietnamese Australian controls. A significant difference in the distribution of the HIV-1 subtypes was demonstrated, with greater than 50% of Vietnamese Australian IDU shown to be infected with CRF01_AE-the predominant subtype in Southeast Asia, rather than subtype B, which dominates the Australian epidemic and which was found in 89.5% of the non-Vietnamese controls. The genetic diversity of the CRF01_AE epidemic in Vietnamese Australian IDUs was substantially lower that that of the background subtype B, consistent with a more recent introduction of a limited number of viral strains from Vietnam. These results support public health policy targeting Australian IDUs of Vietnamese ethnicity as a distinct vulnerable population.
Collapse
Affiliation(s)
- Claire E Ryan
- The Macfarlane Burnet Institute for Medical Research and Public Health, Prahran, Victoria, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Birch C, Middleton T, Hales G, Cooper D, Law M, Crowe S, Hoy J, Emery S. Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing. J Acquir Immune Defic Syndr 2003; 32:57-61. [PMID: 12514414 DOI: 10.1097/00126334-200301010-00008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We investigated the evolution of HIV reverse transcriptase (RT)- and protease-associated antiretroviral (ARV) drug resistance mutations during the time taken to perform genotypic drug resistance testing. Thirty treatment-experienced patients who were adherent to therapy and who underwent genotypic drug resistance testing provided blood samples at randomization and when reviewing the test results (baseline). Patients remained on their existing therapy between randomization and baseline. The predominant HIV strains in 10 patients (33%) either lost and/or gained primary RT inhibitor (RTI)- or protease inhibitor (PI)-associated resistance mutations during the testing period. Of the 9 patients with RT mutations, 2 lost, 5 gained, and 2 both lost and gained RTI resistance mutations. One patient gained a significant PI-associated resistance mutation on an existing PI-resistant background. The evolution that occurred in the RT may have altered the effectiveness of subsequent ARV therapy in some patients. Neither viral load at randomization, ARV drug class used at randomization, time between collection of blood samples, duration of current therapy, nor number of ARV drugs used influenced gain or loss of resistance mutations. There was a significant association between duration of previous ARV therapy and gain of RTI-associated resistance mutations ( p =.02), however. In general, our results suggest that patients should continue current therapy until test results are available. A few patients would be expected to gain ARV drug-associated resistance mutations during this time, however.
Collapse
Affiliation(s)
- Chris Birch
- Victorian Infectioud Diseases Reference Laboratory, North Melbourne, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Middleton T, Smith D, Larder B, Law M, Birch C. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. HIV Clin Trials 2001; 2:445-52. [PMID: 11742431 DOI: 10.1310/yhge-07y8-t3xf-f6vt] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To relate baseline plasma HIV genotypic and virtual phenotypic antiretroviral drug susceptibility to subsequent virological response in patients receiving saquinavir (SQV)-enhancing therapy. Individuals were randomized to receive stavudine (d4T), SQV, and one of ritonavir, nelfinavir, or delavirdine to enhance SQV blood levels. METHOD The protease and reverse transcriptase baseline sequences of 31 treatment-experienced patients were analyzed by genotype and virtual phenotype and were related to viral load at weeks 12 and 24. Genotypic resistance to SQV was defined by the presence of G48V and/or L90M mutations in the protease gene. Potential cross-resistance to d4T in zidovudine (ZDV)-experienced individuals was defined by the presence of thymidine-associated mutations in the reverse transcriptase gene. RESULTS ZDV-associated mutations did not affect the virological response at 24 weeks. Individuals who were sensitive to SQV at baseline as determined by either genotyping or virtual phenotyping showed a greater decrease in viral load at week 24 than those resistant to SQV, irrespective of treatment arm. By genotyping, SQV-sensitive individuals had a median log decrease of 1.12 compared to 0.32 for those individuals who were SQV resistant. By virtual phenotyping, SQV-sensitive individuals had a median log decrease of 1.0 compared to a rise of 0.08 in resistant individuals. CONCLUSION Thymidine analogue-associated mutations at baseline did not influence the response to subsequent therapy involving d4T. Individuals who were sensitive or resistant to SQV by genotyping or virtual phenotyping responded to SQV-enhancing regimens, but the virological response was greater in those who were sensitive.
Collapse
Affiliation(s)
- T Middleton
- Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia.
| | | | | | | | | |
Collapse
|
10
|
Haddad DN, Birch C, Middleton T, Dwyer DE, Cunningham AL, Saksena NK. Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells. AIDS 2000; 14:2273-81. [PMID: 11089615 DOI: 10.1097/00002030-200010200-00008] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To determine the overall distribution of drug-resistance mutations to nucleoside reverse transcriptase inhibitors of HIV strains recovered from the lymph nodes (LN) and peripheral blood mononuclear cell (PBMC) compartments of four HIV-infected patients receiving zidovudine and didanosine and to compare them with antiretroviral-naive patients. DESIGN Molecular comparison of major and minor HIV-1 env and pol region variants residing in LN and PBMC compartments. MATERIALS AND METHODS Proviral DNA sequences were amplified by PCR from both PBMC and LN compartments, cloned into PGEM-T II Easy vector and sequenced. The clones were subjected to molecular and phylogenetic analysis. RESULTS Comparison of PBMC and LN-derived HIV-1 variants in the env V3 region showed that nucleotide and amino acid variability was a characteristic feature of LN-derived variants. In contrast, a majority of resistance mutations to reverse transcriptase inhibitors were localized in the PBMC compartment rather than in LN, which is thought to be a reservoir of HIV. CONCLUSIONS Distinct compartmentalization or independent evolution of pol and env gene variants between LN and PBMC could be due to the differential selection pressure imposed by the combination drug regimen, hence the bimodal distribution of resistance variants between LN and PBMC compartments.
Collapse
Affiliation(s)
- D N Haddad
- Retroviral Genetics Laboratory, Center for Virus Research, Westmead Millennium Institutes, Westmead Hospital, NSW, Sydney, Australia
| | | | | | | | | | | |
Collapse
|
11
|
Sebire K, McGavin K, Land S, Middleton T, Birch C. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol 1998; 36:493-8. [PMID: 9466765 PMCID: PMC104566 DOI: 10.1128/jcm.36.2.493-498.1998] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We investigated the effects of conditions often encountered during handling, transit, and storage of blood specimens on the quantity of detectable human immunodeficiency virus (HIV) RNA in plasma. HIV RNA copy numbers were measured with a commercially available assay (the Amplicor HIV-1 Monitor test kit). Variables examined were the time to processing of blood and plasma, the holding temperature of blood and plasma prior to processing, the effect of freezing and thawing of plasma, and the use of different anticoagulants. The relationship between the HIV RNA copy number and the HIV isolation rate by peripheral blood mononuclear cell (PBMC) coculture was also examined. We found that RNA copy numbers were maintained to within 0.5 log10 (approximately threefold) in blood and plasma samples held at room temperature or 4 degrees C for up to 3 days and remained stable despite (limited) freezing and thawing of the plasma. HIV RNA copy numbers were also maintained after long-term storage of plasma at -70 degrees C. The ability to isolate HIV from PBMCs was directly proportional to the HIV RNA copy number.
Collapse
Affiliation(s)
- K Sebire
- State Reference Laboratory for HIV Isolation, Victorian Infectious Diseases Reference Laboratory, Fairfield, Australia
| | | | | | | | | |
Collapse
|
12
|
Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF, Fesik SW. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem 1997; 40:3144-50. [PMID: 9379433 DOI: 10.1021/jm9703404] [Citation(s) in RCA: 134] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The E2 protein is required for the replication of human papillomaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas. Using an NMR-based screen, we tested compounds for binding to the DNA-binding domain of the HPV-E2 protein. Three classes of compounds were identified which bound to two distinct sites on the protein. Biphenyl and biphenyl ether compounds containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of E2 to DNA. Benzophenone-containing compounds which lack a carboxylic acid group bind to the beta-barrel formed by the dimer interface and exhibit negligible effects on the binding of E2 to DNA. Structure-activity relationships from the biphenyl and biphenyl ether compounds were combined to produce a compound [5-(3'-(3",5"-dichlorophenoxy)-phenyl)-2,4-pentadienoic acid] with an IC50 value of approximately 10 microM. This compound represents a useful lead for the development of antiviral agents that interfere with HPV replication and further illustrates the usefulness of the SAR by NMR method in the drug discovery process.
Collapse
Affiliation(s)
- P J Hajduk
- Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Epstein-Barr virus nuclear antigen 1 (EBNA1) can bind specifically to two clusters of sites within the Epstein-Barr virus plasmid origin of DNA replication (oriP). EBNA1 activates DNA replication mediated by oriP and can also activate transcription and retain DNA in cells when bound site specifically. EBNA1 bound to oriP physically links the two clusters of EBNA1-binding sites, resulting in loop formation by the intervening DNA. To elucidate the contribution of DNA linking by EBNA1 to its biological activities, we identified regions within it that can independently link DNAs to which they are bound. An electrophoretic mobility shift assay was used to detect this activity. Proteins which link DNA aggregate that DNA into large lattices. Proteins which cannot link DNA but still bind to DNA retard the mobility of that DNA but do not cause it to form lattices. Amino-terminal truncations were used to map the amino-terminal limit of a minimal DNA-linking domain approximately to amino acid 372 of EBNA1. To map the carboxy-terminal limit of this minimal domain, fusion proteins containing the DNA-binding domain of GAL4 and fragments of EBNA1 were generated and studied. This approach identified the carboxy-terminal limit of this minimal domain to be approximately amino acid 391 and verified its amino-terminal limit. Internal deletions within a truncated EBNA1 derivative verified the importance of this region. Two additional fragments of EBNA1, each of which independently conferred DNA-linking activity on the domain of GAL4 which binds DNA, were identified within amino acids 54 to 89 and amino acids 331 to 361. Therefore, EBNA1 contains at least three regions that can act independently to link DNAs and that may act in concert within intact EBNA1.
Collapse
Affiliation(s)
- D Mackey
- McArdle Laboratory for Cancer Research, Department of Oncology, Medical School, University of Wisconsin-Madison, USA
| | | | | |
Collapse
|
14
|
Abstract
The capacity to bind the Epstein-Barr viral protein EBNA1 increases the retention of the plasmid in dividing cells. This retention requires binding of multiple EBNA1 molecules for function, although significant retention activity is seen with fewer EBNA1 binding sites than are required to activate replication or transcription. The regions of EBNA1 that are required for increased plasmid retention overlap with those required for activation of transcription and replication. The similarities in traits of EBNA1 that are required for support of DNA replication and retention of plasmid DNA indicate that both may be mediated by interactions with an overlapping set of cellular proteins.
Collapse
Affiliation(s)
- T Middleton
- McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706
| | | |
Collapse
|
15
|
Abstract
DNA replication from the plasmid origin of replication of Epstein-Barr virus requires one viral protein, EBNA1. This protein also acts as a transcriptional activator. Mutational analyses of EBNA1 have led to the conclusion that it supports transcription and DNA replication similarly. Such analyses have not probed the DNA-binding domain of EBNA1. To test whether domains of EBNA1 specifically required for either transcription or replication lie within its DNA-binding domain, we constructed a functional transcriptional activator by placing the EBNA1 DNA-binding domain in the context of the activation domains of the estrogen receptor. This hybrid protein did not support DNA replication, which indicates that the DNA-binding domain does not contain a replication-specific domain that can function along with heterologous transcriptional activating domains.
Collapse
Affiliation(s)
- T Middleton
- McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706
| | | |
Collapse
|
16
|
Abstract
The plasmid origin of DNA replication of Epstein-Barr virus, oriP, is replicated once per cell division, employing cellular replication machinery and only one viral protein. To understand how replication from this origin is initiated and regulated, we purified this viral protein, EBNA1. EBNA1 was expressed in CV-1p cells by using an infectious simian virus 40 vector containing the EBNA1 gene. It was purified in two chromatographic steps to apparent homogeneity. The purified protein is capable of supporting transcription of the luciferase gene from a reporter plasmid carrying the FR enhancer element to which EBNA1 binds. EBNA1 does not have oriP-dependent ATPase activity, indicating that it does not carry out an energy-dependent step in the initiation of DNA replication. However, EBNA1 does mediate an association between the two elements of oriP. We measured this association by binding one of the elements, the enhancer element, to a solid matrix and measuring retention by this element of the other one, the initiator element, in the presence of EBNA1. This retention is specific for DNA fragments containing EBNA1-binding sites. EBNA1 thus can link the two elements of the origin, providing a locally high concentration of EBNA1 at the site of initiation of DNA replication. We propose that this association is important either (i) to affect DNA structure to allow a cellular helicase to initiate DNA strand separation or (ii) to bind replication proteins to bring them to the origin of replication.
Collapse
MESH Headings
- Adenosine Triphosphatases/metabolism
- Antigens, Viral/genetics
- Antigens, Viral/isolation & purification
- Antigens, Viral/metabolism
- Base Sequence
- Cloning, Molecular
- DNA Replication
- DNA, Viral/biosynthesis
- DNA, Viral/metabolism
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/isolation & purification
- DNA-Binding Proteins/metabolism
- Electrophoresis, Polyacrylamide Gel
- Enhancer Elements, Genetic
- Epstein-Barr Virus Nuclear Antigens
- Herpesvirus 4, Human/genetics
- Herpesvirus 4, Human/immunology
- Herpesvirus 4, Human/metabolism
- Molecular Sequence Data
- Plasmids
- Transcription, Genetic
Collapse
Affiliation(s)
- T Middleton
- McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706
| | | |
Collapse
|
17
|
Su W, Middleton T, Sugden B, Echols H. DNA looping between the origin of replication of Epstein-Barr virus and its enhancer site: stabilization of an origin complex with Epstein-Barr nuclear antigen 1. Proc Natl Acad Sci U S A 1991; 88:10870-4. [PMID: 1660153 PMCID: PMC53033 DOI: 10.1073/pnas.88.23.10870] [Citation(s) in RCA: 90] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Epstein-Barr nuclear antigen 1 (EBNA-1) is the only viral protein required to support replication of Epstein-Barr virus during the latent phase of its life cycle. The DNA segment required for latent replication, oriP, contains two essential binding regions for EBNA-1, termed FR and DS, that are separated by 1 kilobase pair. The FR site appears to function as a replicational enhancer providing for the start of replication at the DS site. We have used electron microscopy to visualize the interaction of EBNA-1 with its binding sites and to study the mechanism for communication between the FR and DS sites. We have found that DNA-bound EBNA-1 forms a DNA loop between the FR and DS sites. From these results, we suggest that EBNA-1 bound to the replicational enhancer acts by a DNA-looping mechanism to facilitate the initiation of DNA replication. Occupancy of the DS site alone is highly sensitive to competition with nonspecific DNA. In contrast, occupancy of the DS site by looping from FR is largely resistant to the competitor DNA. These experiments support the concept that enhancers act in cis from nearby sites to provide a high local concentration of regulatory proteins at their target sites and to stabilize regulatory interactions.
Collapse
MESH Headings
- Animals
- Antigens, Viral/metabolism
- Antigens, Viral/ultrastructure
- Base Sequence
- Binding, Competitive
- Cell Line
- Cell Nucleus/ultrastructure
- DNA Replication
- DNA, Viral/genetics
- DNA, Viral/ultrastructure
- Enhancer Elements, Genetic
- Epstein-Barr Virus Nuclear Antigens
- Herpesvirus 4, Human/genetics
- Herpesvirus 4, Human/physiology
- Herpesvirus 4, Human/ultrastructure
- Microscopy, Electron
- Molecular Sequence Data
- Nucleic Acid Conformation
- Protein Binding
- Protein Conformation
- Virus Replication
Collapse
Affiliation(s)
- W Su
- Division of Biochemistry and Molecular Biology, University of California, Berkeley 94720
| | | | | | | |
Collapse
|
18
|
Abstract
EBV immortalizes human B lymphocytes efficiently. Ten of its approximately 100 genes are expressed in these proliferating lymphoblasts and are candidates for mediating the changes central to the immortalization of the cell. Enough has been learned now about three of these viral genes to indicate that they are likely to be required for immortalization. As more is learned, additional genes of EBV will probably be found to support the process of immortalization of the host cell. EBNA-2 has been shown genetically to be required for EBV to immortalize an infected B lymphocyte. The biochemical activities of EBNA-2 that constitute this requirement have not been identified. Many experiments indicate that EBNA-2 affects the accumulation of specific viral and cellular RNAs. These effects, however, can be detected only in certain EBV-negative B-lymphoblastoid cells. It is, therefore, not clear that the known effects of EBNA-2 adequately explain its ubiquitous requirement in the immortalization of primary human B lymphocytes. LMP is likely to be required for immortalization because it can affect the growth properties of established human lymphoid and epithelial cells and can transform at least two established rodent cells to proliferate in an anchorage-independent manner. The structure of this viral protein, its position in the plasma membrane, many of its biochemical properties, as well as studies of its mutant derivatives are consistent with its acting as a growth factor receptor or affecting the activity of such a receptor. However, no biochemical activity has been assigned directly to LMP, and both its mechanism of action and its possible contribution to immortalization by EBV remain enigmatic. EBNA-1 presumably is required for EBV to immortalize a B lymphocyte because it is essential for the initiation of plasmid DNA replication by EBV. Circumstantial observations indicate also that EBNA-1 is probably necessary for sustaining viral DNA replication in the proliferating cell population. EBNA-1 may well affect the regulation of transcription of viral genes that themselves are required for immortalization. These roles of EBNA-1 are performed in part by its site-specific binding to the elements of oriP required in cis for the replication of EBV plasmid DNAs. It is probable that EBNA-1 also binds both to a set of cellular proteins that function in transcription and to a nonidentical set of cellular proteins that function in replication. EBV effects a fascinating phenotypic change in B lymphocytes it infects. It does so by using several viral genes that alter the physiology of the cell by different means.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- T Middleton
- McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706
| | | | | | | |
Collapse
|
19
|
Sternås L, Middleton T, Sugden B. The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells. J Virol 1990; 64:2407-10. [PMID: 2157896 PMCID: PMC249405 DOI: 10.1128/jvi.64.5.2407-2410.1990] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Epstein-Barr nuclear antigen 1 (EBNA-1) is the only viral protein required to support latent replication of Epstein-Barr virus (EBV). To assess the likelihood that EBNA-1 regulates the amount of EBV DNA in a cell, we measured the average numbers of EBNA-1 molecules and EBV DNA molecules per cell in different clones of cells. The amount of EBNA-1 protein present in recently established lymphoblastoid cell lines was measured with affinity-purified anti-EBNA-1 antibodies, and viral DNA was measured by nucleic acid hybridization. The average levels of EBNA-1 protein varied little between these cell lines, whereas the average amount of viral DNA present varied substantially; consequently, these numbers were not correlated. There is no apparent relationship between amounts of EBNA-1 and viral DNA.
Collapse
Affiliation(s)
- L Sternås
- McArdle Laboratory for Cancer Research, University of Wisconsin-Madison 53706
| | | | | |
Collapse
|
20
|
Middleton T, Herlihy WC, Schimmel PR, Munro HN. Synthesis and purification of oligoribonucleotides using T4 RNA ligase and reverse-phase chromatography. Anal Biochem 1985; 144:110-7. [PMID: 3985307 DOI: 10.1016/0003-2697(85)90091-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
T4 RNA ligase has been used to construct a series of defined oligoribonucleotides. Hexamer or pentamer blocks were synthesized first by multiple additions of mononucleotide diphosphates to trimers with T4 RNA ligase and removal of the terminal phosphate with alkaline phosphatase; inhibitors of the ligase were removed by passing the sample over a 1-ml reverse-phase octadecasilyl column. The two nucleotide blocks were then ligated to give undecamers. Yields for the individual ligations ranged from 85 to 100% for acceptors lacking uridines and at least 70% for those containing uridines. The overall yield of the undecamer relative to the starting trimers was about 10%. Each round of ligation averaged about 8 h; the time required to synthesize each undecamer was 1 to 2 weeks. Optimization of the steps to achieve this is described in detail.
Collapse
|
21
|
Middleton T. DEAFNET--the word's getting around: local implementation of telecommunications networks for deaf users. Am Ann Deaf 1983; 128:613-618. [PMID: 6227220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
22
|
Middleton T. Report of a Case of Ovarian Disease, with a Few Brief Remarks Upon Ovariotomy. West J Med 1846; 10:153-5. [DOI: 10.1136/bmj.s1-10.14.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
23
|
Middleton T. Report of a Case of Ovarian Disease, with a Few Brief Remarks upon Ovariotomy. West J Med 1846; 10:141-3. [DOI: 10.1136/bmj.s1-10.13.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|